Treatment outcome and prognostic factors for adult patients with medulloblastoma: The Rare Cancer Network (RCN) experience

Basit Öğe Kaydı
dc.contributor.authorAtalar, Banu
dc.contributor.authorOzsahin, Mahmut
dc.contributor.authorCall, Jason
dc.contributor.authorNapieralska, Aleksandra
dc.contributor.authorKamer, Serra
dc.contributor.authorVilla, Salvador
dc.contributor.authorErpolat, Petek
dc.contributor.authorNegretti, Laura
dc.contributor.authorLassen-Ramshad, Yasmin
dc.contributor.authorOnal, Cem
dc.contributor.authorAkyurek, Serap
dc.contributor.authorUgurluer, Gamze
dc.contributor.authorBaumert, Brigitta G.
dc.contributor.authorServagi-Vernat, Stephanie
dc.contributor.authorMiller, Robert C.
dc.contributor.authorOzyar, Enis
dc.contributor.authorSio, Terence T.
dc.date.accessioned2019-10-27T10:07:08Z
dc.date.available2019-10-27T10:07:08Z
dc.date.issued2018
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground and purpose: The optimal treatment for adults with newly diagnosed medulloblastoma (MB) has not been defined. We report a large series of cases from the Rare Cancer Network. Material and methods: Thirteen institutions enrolled 206 MB patients who underwent postoperative radiotherapy (RT) between 1976 and 2014. Log-rank univariate and Cox-modeled multivariate analyses were used to analyze data collected. Results: Median patient age was 29 years; follow-up was 31 months. All patients had the tumor resected; surgery was complete in 140 (68%) patients. Postoperative RT was given in 202 (98%) patients, and 94% received craniospinal irradiation (CSI) and, usually, a posterior fossa boost. Ninety-eight (48%) patients had chemotherapy, mostly cisplatin and vincristine-based. The 10-year local control, overall survival, and disease-free survival rates were 46%, 51%, and 38%, respectively. In multivariate analyses, Karnofsky Performance Status (KPS) >= 80 and CSI were significant for disease-free and overall survival (P <= .04 for all); receiving chemotherapy and KPS >= 80 correlated with better local-control rates. Conclusions: Patients with high KPS who received CSI had better rates of disease-free and overall survival. Chemotherapy was associated with better local control. These results may serve as a benchmark for future studies designed to improve outcomes for adults with medulloblastoma. (C) 2018 Elsevier B. V. All rights reserved. Radiotherapy and Oncology 127 (2018) 96-102en_US
dc.identifier.doi10.1016/j.radonc.2017.12.028en_US
dc.identifier.endpage102en_US
dc.identifier.issn0167-8140
dc.identifier.issn1879-0887
dc.identifier.issue1en_US
dc.identifier.pmid29373196en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage96en_US
dc.identifier.urihttps://doi.org/10.1016/j.radonc.2017.12.028
dc.identifier.urihttps://hdl.handle.net/11454/30522
dc.identifier.volume127en_US
dc.identifier.wosWOS:000433102000015en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Ireland Ltden_US
dc.relation.ispartofRadiotherapy and Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdult medulloblastomaen_US
dc.subjectChemotherapyen_US
dc.subjectCraniospinalen_US
dc.subjectMultimodalityen_US
dc.subjectRadiotherapyen_US
dc.subjectRare Cancer Network (RCN)en_US
dc.titleTreatment outcome and prognostic factors for adult patients with medulloblastoma: The Rare Cancer Network (RCN) experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu